Oakley Capital Investments Limited Oakley invests in three dental labs businesses (8619I)

TIDMOCI

RNS Number : 8619I

Oakley Capital Investments Limited

10 August 2023

10 August 2023

Oakley Capital Investments Limited

Oakley Capital Investments Limited(1) ("OCI") is pleased to announce that Oakley Capital Fund V(2) ("Fund V") has, subject to regulatory approval, agreed to acquire Flemming Dental, Excent, and Artinorway Group (combined as "the Company") in a carve-out from European Dental Group ("EDG"), a leading pan-European oral care and services provider, to form one of the leading dental laboratories groups in Europe.

OCI's indirect contribution via Fund V is expected to be c.GBP35 million.

Note that the above figure only relates to OCI's share of Oakley's overall investment in Flemming Dental, Excent, and Artinorway Group.

Further details on the transaction can be found in the below announcement from Oakley Capital(3.)

Oakley Capital invests in Flemming Dental, Excent and Artinorway Group

Oakley Capital ("Oakley"), a leading pan-European private equity investor, is pleased to announce that Oakley Capital Fund V ("Fund V") has agreed to acquire Flemming Dental, Excent, and Artinorway Group (combined as the "Company") in a carve-out from European Dental Group ("EDG"), a leading pan-European oral care and services provider, to form one of the leading dental laboratories groups in Europe.

The Company provides a comprehensive range of services, including the design and manufacture of dental prostheses (crowns, bridges and dentures) and orthodontics (braces, retainers and aligners), utilising technology including CAD software, computer-aided milling and 3D printing, as well as local craftmanship. The Company currently services c.5,000 clinics across nearly 70 dental laboratories throughout Europe.

Oakley will work closely with the management to establish Flemming Dental, Excent and Artinorway Group as an independent business and to become a leader in the global dental lab market. Through this transaction, Oakley is leveraging its network of entrepreneurs, partnering with Hidde Hoeve, the co-founder of Excent Tandtechniek, a group of dental laboratories acquired by EDG in 2018. The collaboration between Oakley and the Company's experienced management team will see the execution of an ambitious growth strategy, driven by organic growth, international expansion and targeted M&A.

Through Fund V's investment, the Company will benefit from Oakley's extensive expertise in digitalisation, helping the Company to capitalise on technological innovation in the dental lab industry and the rapid digital transformation of the market. Fund V's investment will enable the Company to accelerate innovation and the adoption of cutting-edge technology, providing solutions with unparalleled precision for dental clinics and their patients across Europe and beyond. The European dental lab market is large and growing with strong customer stickiness, valued at approximately EUR10 billion today, and is also highly fragmented offering compelling opportunities for value creation through buy-and-build, which is an area Oakley has extensive expertise in.

The transaction is subject to regulatory approval.

Oakley Capital Managing Partner and co-Founder Peter Dubens commented:

"This is a key inflection point for the dental laboratory industry, with rapid digitalisation poised to revolutionise dental design and manufacturing, and patient care. We look forward to working closely with Hidde Hoeve and the management team as we establish Flemming Dental, Excent and Artinorway Group as an independent company and leverage transformational new technologies to unlock its full potential for future growth."

Excent co-founder and CEO of the new combined entity Hidde Hoeve commented:

"In Oakley we have the ideal partner to support Flemming Dental, Excent and Artinorway Group as they begin the next chapter as an independent business. We are well positioned to capitalise on the accelerating digitalisation of dental laboratories. Together with the current management, we will maintain focus on our clients, local craftsmanship and innovation. Oakley's expertise will be invaluable as we execute our growth strategy to become the leader in the global dental lab market."

- ends -

For further information please contact:

Oakley Capital Limited

[phone]

Steven Tredget

Greenbrook Communications Limited

[phone]

Rob White / Michael Russell

Liberum Capital Limited (Financial Adviser & Broker)

[phone]

Chris Clarke / Darren Vickers / Owen Matthews

Notes:

LEI Number: 213800KW6MZUK12CQ815

(1) About Oakley Capital Investments Limited ("OCI")

OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds (2) .

A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/

The contents of the OCI website are not incorporated into, and do not form part of, this announcement.

(2) The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV, Oakley Capital V and Oakley Capital Origin Fund and are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement. The Oakley family of funds also includes Oakley PROfounders Fund III and Oakley Touring Venture Fund, which are venture capital funds focused on investments in entrepreneur-led, disruptive, technology led companies.

For more information on the Oakley Fund strategies in which OCI invests, please click here.

(3) Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQKKLFBXVLZBBQ

(END) Dow Jones Newswires

August 10, 2023 02:00 ET (06:00 GMT)